Remove 2010 Remove Food and Drug Administration Remove Healthcare
article thumbnail

What do future healthcare CEOs look like?

World of DTC Marketing

American healthcare is in trouble. I have to laugh when I hear that a pharma company is patient-centric because that’s become a slogan to make employees feel good about themselves while the costs of prescription drugs increase every year. Highest-paid CEOs in 2019: Who made the list from healthcare. This has to end.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few?

Marketing 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

THEPM360TRAILBLAZER AWARD WINNER – Lifetime Achievement Award – Adam Schechter, CEO and Chairman, Labcorp

PM360

He was Executive VP and President of Merck’s Global Human Health Division from 2010 to 2019. Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. Food and Drug Administration (FDA) approval.

Ethics 59
article thumbnail

For rare disease patients in Mainland China, hope of greater access to treatment

Clarivate

Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. The list, designed to serve as a reference point for prioritized drug review and evaluation policies, included 121 rare diseases. [8].

article thumbnail

Pfizer’s vaccine results “a political conspiracy”

World of DTC Marketing

According to JAMA , “between January 2010 and June 2020, the FDA approved 21 vaccines, most commonly for influenza (5 [23.8%]) and meningococcus (5 [23.8%]). The median premarket clinical development period (investigational new drug submission to FDA approval) was 8.1 Ken Catalino / Creators Syndicate.

article thumbnail

Three biggest threats to healthcare

World of DTC Marketing

Right now, voters are worried about inflation and rising fuel prices, but they ignore the imminent threats to their healthcare. American healthcare continues to be under assault, and unless we address these issues, a severe health issue could bankrupt families. THREAT 3: RISING HEALTHCARE COSTS. THREAT 1: OBESITY AND DIABETES.